Clene Inc.是一家临床阶段的纳米技术制药公司,从投资公司得到多重目标价格上涨。 Clene Inc., a clinical-stage nanotech pharmaceutical firm, receives multiple target price increases from investment firms.

临床阶段的制药公司Clene Inc. 已从EF Hutton Acquisition Co获得"强购"升级. 此外,HC Wainwright将其目标价格从7.00美元提高到31.00美元,而Canaccord Genuity则设定了94.00美元的目标,Benchmark则设定了100美元的目标. Clene Inc., a clinical-stage pharmaceutical firm, has received a "strong-buy" upgrade from EF Hutton Acquisition Co. Additionally, HC Wainwright raised its price target from $7.00 to $31.00, while Canaccord Genuity set a target of $94.00, and Benchmark established a $100.00 target. Clene侧重于清洁表面纳米技术治疗,其主要候选者CNM-Au8在临床试验中。 Clene focuses on clean-surfaced nanotechnology therapeutics, with its lead candidate CNM-Au8 in clinical trials. 该公司的市场上限为3 940万美元。 The company's market cap is $39.40 million.